ID16266A - Perlakuan dan pencegahan pankreatitis - Google Patents

Perlakuan dan pencegahan pankreatitis

Info

Publication number
ID16266A
ID16266A IDP970826A ID970826A ID16266A ID 16266 A ID16266 A ID 16266A ID P970826 A IDP970826 A ID P970826A ID 970826 A ID970826 A ID 970826A ID 16266 A ID16266 A ID 16266A
Authority
ID
Indonesia
Prior art keywords
prevention
treatment
pancreatitical
troglitazone
pancreatitis
Prior art date
Application number
IDP970826A
Other languages
English (en)
Inventor
Toshihiko Fujiwara
Hiroyoshi Horikoshi
Masaharu Fukami
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of ID16266A publication Critical patent/ID16266A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Catching Or Destruction (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IDP970826A 1996-03-18 1997-03-14 Perlakuan dan pencegahan pankreatitis ID16266A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6106396 1996-03-18
JP25020196 1996-09-20

Publications (1)

Publication Number Publication Date
ID16266A true ID16266A (id) 1997-09-18

Family

ID=26402115

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP970826A ID16266A (id) 1996-03-18 1997-03-14 Perlakuan dan pencegahan pankreatitis

Country Status (19)

Country Link
US (1) US5753681A (id)
EP (1) EP0796618B1 (id)
KR (1) KR100542778B1 (id)
CN (1) CN1178657C (id)
AT (1) ATE212548T1 (id)
AU (1) AU708315B2 (id)
CA (1) CA2200126C (id)
CZ (1) CZ283968B6 (id)
DE (1) DE69710111T2 (id)
DK (1) DK0796618T3 (id)
ES (1) ES2167678T3 (id)
HK (1) HK1003051A1 (id)
HU (1) HUP9700598A3 (id)
ID (1) ID16266A (id)
IL (1) IL120443A (id)
NO (1) NO313179B1 (id)
NZ (1) NZ314406A (id)
PT (1) PT796618E (id)
TW (1) TW548102B (id)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
HU228193B1 (en) * 1997-10-08 2013-01-28 Sankyo Co Imidazole fused heterocyclic compounds, process for their preparation, pharmaceutical compositions containing the same and their use
DE69914557T2 (de) * 1998-03-30 2005-01-05 Japan Tobacco Inc. Verfahren zur herstellung einer isooxazolidindion-verbindung
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
ES2237929T3 (es) * 1998-07-21 2005-08-01 Smithkline Beecham Plc Uso del activador de la asimilacion de glucosa rosiglitazona para reducir la apoptosis inducida por isquemia de celulas beta pancreaticas, celulas endoteliales y celulas neuronales.
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
AU5760900A (en) * 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
DE60020573T2 (de) 1999-08-23 2006-03-16 Kyorin Pharmaceutical Co., Ltd. Substituierte benzylthiazolidin-2,4-dion derivate
KR100738245B1 (ko) 1999-08-23 2007-07-12 교린 세이야꾸 가부시키 가이샤 치환된 벤질티아졸리딘-2,4-디온 유도체
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
EP2413967A1 (en) 2009-04-01 2012-02-08 F. Hoffmann-La Roche AG Treatment of insulin-resistant disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
DE3343141A1 (de) * 1983-11-29 1985-06-05 Hermann P.T. 7400 Tübingen Ammon Verwendung von cystein-derivaten oder deren salzen, zur steigerung der insulinsekretion der langerhans'schen inseln der bauchspeicheldruese
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
WO1986007056A1 (en) * 1985-05-21 1986-12-04 Pfizer Inc. Hypoglycemic thiazolidinediones
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
DK375789A (da) * 1988-08-18 1990-02-19 Syntex Inc Peptidderivater
JP2845743B2 (ja) * 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
AU7118694A (en) * 1993-07-13 1995-02-13 Janica M. Moizis Fastener for clothing
ATE179709T1 (de) * 1993-12-27 1999-05-15 Japan Tobacco Inc Isoxazolidindionderivate und deren verwendung
CZ289317B6 (cs) * 1994-04-11 2002-01-16 Sankyo Company Limited Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
FR2721608B1 (fr) * 1994-06-22 1996-07-19 Rhone Poulenc Rorer Sa Dérivés de thiazolidine, leur préparation et les médicaments les contenant.
CA2159938A1 (en) * 1994-10-07 1996-04-08 Hiroaki Yanagisawa Oxime derivatives, their preparation and their therapeutic use
IL118474A (en) * 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
CA2200126C (en) 2006-08-15
PT796618E (pt) 2002-06-28
DE69710111D1 (de) 2002-03-14
AU708315B2 (en) 1999-07-29
DE69710111T2 (de) 2002-10-02
KR19980023975A (ko) 1998-07-06
HUP9700598A3 (en) 1998-10-28
ES2167678T3 (es) 2002-05-16
EP0796618A1 (en) 1997-09-24
KR100542778B1 (ko) 2006-04-14
NO971219L (no) 1997-09-19
IL120443A (en) 2000-07-16
NZ314406A (en) 2000-12-22
EP0796618B1 (en) 2002-01-30
CZ79097A3 (en) 1997-10-15
US5753681A (en) 1998-05-19
HUP9700598A2 (hu) 1998-09-28
MX9702058A (es) 1998-03-31
HU9700598D0 (en) 1997-05-28
TW548102B (en) 2003-08-21
CA2200126A1 (en) 1997-09-18
HK1003051A1 (en) 1998-10-09
DK0796618T3 (da) 2002-05-06
AU1628597A (en) 1997-09-25
ATE212548T1 (de) 2002-02-15
NO971219D0 (no) 1997-03-17
NO313179B1 (no) 2002-08-26
CN1178657C (zh) 2004-12-08
CN1170575A (zh) 1998-01-21
IL120443A0 (en) 1997-07-13
CZ283968B6 (cs) 1998-07-15

Similar Documents

Publication Publication Date Title
ID16266A (id) Perlakuan dan pencegahan pankreatitis
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
HUT67742A (en) Phosphono-oxymethyl-ethers of taxane derivatives
EP0908186A3 (en) Method for treating pain
FI905531A0 (fi) Transdermalisk anvaendning av 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobensotiazol.
MA23603A1 (fr) Derives d'oxalylamino-benzafuranne et benzothienyle.
ATE253063T1 (de) 5-ht1f-agonisten
DE69808620T2 (de) Universell verwendbares bluttplasma
ES2127396T3 (es) Inhibidores aromaticos de acetilcolinesterasa.
MX9401175A (es) Inhibidores de la acetilcolinesterasa sililada.
DE69825605D1 (de) Behandlung der schizophrenie und der psychose
ID25478A (id) Agonis 5-ht1f
TR199600117A2 (tr) Ikame edilen benzolsülfonilüre ve tiyoüre, bu maddelerin elde edilmesi ve eczanecilikle ilgili maddelerin bu bilesimler ve bu bilesimleri iceren iyilestirici maddelere dayanarak kullanilmasi ile ilgili usul.
DK453387A (da) Middel til behandling af arteriosklerose og forhindring af blodpladekoagulation
IT1303621B1 (it) Nastro trasportatore per il trattamento di materiali.
MX9704035A (es) 1,1-dioxidos de 2-(fosfiniloximetil)-1,2,5-tiadiazolidin-3-ona substituidos y composiciones y metodo de uso de los mismos.
FR2714717B1 (fr) Procédé d'oxydation des imbrûlés de matières hydrocarbonées.
ATE262527T1 (de) Zur vorbeugung oder behandlung von östrogenabhängigen krankheiten nützliche pyrrolo(2.1.5-cd)indolizin-derivate
GR3036968T3 (en) Adamantyl substituted oxindoles as pharmaceutical agents
NO983418L (no) Fremgangsmåte ved behandling av for, samt forprodukter